Don't wait until manufacturing execution system (MES) configuration to answer these 7 questions. Define your manufacturing process before digitizing it.
- FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
- You Can't CAPA What You Can't Classify
- 6 Modeling Approaches That Make Complex Bioprocess Data Useful
- Building Trust In AI For Computerized System Validation
- A Gentler Cell Line Selection Method Using microRNA
- Controls For Retrieval-Augmented Generation In GxP
- Implementing AI Solutions In GMP While Managing Risk
GUEST COLUMNISTS
-
FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
The proposed revision reflects changes in packaging technology, drug delivery systems, quality risk management, and more that have occurred since 1999's guidance.
-
You Can't CAPA What You Can't Classify
An LLM or agentic error can occur with no component broken in any way the QMS recognizes. Classifying it takes two fields: the error type and the error origination point.
-
6 Modeling Approaches That Make Complex Bioprocess Data Useful
AI algorithms can reduce data dimensionality more faithfully by interpreting multivariate features relevant to prediction or control.
-
Building Trust In AI For Computerized System Validation
Using AI for CSV might feel like the students are grading their own papers. One consultant explains why it's not the same, namely, there are no subjective judgment calls.
-
A Gentler Cell Line Selection Method Using microRNA
Traditional selection stresses surviving cells. New research shows how structurally interacting RNA may use endogenous microRNA for a faster, nontoxic selection process.
-
Controls For Retrieval-Augmented Generation In GxP
Validation teams deal with inherent variability all the time. The same principles for GMP — think visual inspection — can apply to probabilistic AI systems.
-
Implementing AI Solutions In GMP While Managing Risk
When using artificial intelligence in GMP settings, risk management extends far beyond validation. This discussion explores moving AI solutions out of the pilot phase.
BIOSIMILAR WHITE PAPERS
-
A Comprehensive Solution For Adventitious Agent Testing
Modern sequencing methods offer sensitive detection of adventitious and species‑specific viruses. Learn how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.
-
Aggregation In Antibody-Drug Conjugates: Causes And Mitigation9/1/2025
Discover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.
-
ADC Development Grows More Complex — SPR Insights Bring Clarity4/14/2026
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
-
Reliability In Bioprocessing Is Your Competitive Advantage9/11/2026
Equipment reliability is a prerequisite for realizing value from digital transformation, automation, and data-driven initiatives in bioprocess manufacturing.
-
Is Sustainability The Key To Agile Biopharma Manufacturing?3/18/2025
In biologics manufacturing, change is constant. Discover how new innovations and a focus on sustainability have gotten 62% of executives to prioritize eco-friendly practices, which reflects a commitment to long-term viability.
-
Performance Characteristics Of The Mobius® ADC Reactor For Conjugation10/22/2024
Explore results from a series of studies evaluating the mixing performance of an innovative ADC reactor during the conjugation step utilizing a model fluid.
BIOSIMILAR APP NOTES & CASE STUDIES
- Characterization Of PFAS Extractables In Gas Filtration Devices
- mRNA Manufacturing With Fed-Batch In Vitro Transcription
- Multi-Column Chromatography For Efficient Polishing Purification
- Performance Of Mobius® Bag Assemblies With Ultimus® Film In Truck Shipping Simulation Test
- Can Your Biopharma Team Keep Unplanned Downtime At Bay?
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Waltz Health And Fresenius Kabi Expand Direct Access To Biosimilars Through Waltz Connect Platform
- Formycon And Zydus: FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted For Review By FDA
- Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- And Short-Acting G-CSF Options
- Thyme Companies Launches First New Venture, Thyme Therapeutics, To Build A More Sustainable, Lower-Cost Oncology Biosimilar Model
- LOTTE Biologics And Alvotech Announce US-Based Manufacturing Agreement To Increase Global Supply
- Kamada Announces Expansion Of Biosimilars Portfolio With The Launch Of Two Additional Products In Israel
- Orion Pharma Announces Agreement With Qilu Pharma Europe For Pembrolizumab Biosimilar For European Market
- Formycon Optimizes Biosimilar Development With AI-Powered Technologies: Digital Solutions Enhance Development Efficiency As Part Of The FYB4GROWTH Strategy
NEWSLETTER ARCHIVE
- 10.08.26 -- Building Trust In AI For Computerized System Validation
- 10.01.26 -- Faster Paths To Biosimilar Equivalence
- 09.24.26 -- Navigating The Regulatory Space To Biosimilar Approval
- 09.17.26 -- Your Collaborator: mAb Productivity And Robustness
- 09.17.26 -- A Much-Improved Approach For Managing Safety Risks